Institutional investors purchased a net $10.3 million shares of IMGN during the quarter ended June 2017 and now own 88.06% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FIDELITY MANAGEMENT & RESEARCH C... Bought 4.8 Million shares of ImmunoGen Inc
MILLENNIUM MANAGEMENT LLC Bought 2.9 Million shares of ImmunoGen Inc
SSGA FUNDS MANAGEMENT, INC. Bought 2.5 Million shares of ImmunoGen Inc